Overview

• Adjusted earnings were $1.30 per share on $11.37 billion in sales, matching the FactSet EPS estimate and coming in just below the $11.39 billion revenue consensus.
• Abbott reaffirmed 7.5%–8% organic sales growth for the year excluding Covid tests and narrowed its full‑year EPS outlook to $5.12–$5.18 with an unchanged midpoint.
• The stock fell nearly 3% in premarket trading to $128.94 after the results.
• Sell‑side commentary noted medtech strength helped offset weaker performance in diagnostics, nutrition and established pharmaceuticals.
• In the year‑earlier quarter, Abbott reported $1.21 EPS on $10.64 billion in sales, indicating year‑over‑year growth.